Carpa Healthcare
Pharmacovigilance
Carpa Healthcare is committed to upholding the highest standards of pharmacovigilance in alignment with the National Agency for Food and Drug Administration and Control (NAFDAC)’s Good Pharmacovigilance Practice (GVP) Guidelines.
Report a side effect!
The World Health Organization defines an adverse drug reaction (ADR) as: ‘A response to a medicine which is noxious (harmful) and unintended and which occurs at doses normally used in man for the prophylaxis (prevention), diagnosis or therapy (treatment) of diseases, or for the modification of physiological function’. In simpler terms, an adverse drug reaction is any unexpected or dangerous reaction to a drug.
If you notice or suspect any undesirable effect linked to a Carpa Healthcare product, please fill the form below. Irrespective of whether you are a customer, patient or healthcare professional. Download the adverse effect form below or fill the online form.
Our Commitment
In accordance with the guidelines of the National Agency for Food and Drug Administration and Control (NAFDAC), the prompt and accurate reporting of Adverse Drug Reactions (ADRs) is a critical component of pharmacovigilance and an essential obligation for all healthcare professionals, pharmaceutical companies, and patients. This practice plays a pivotal role in enhancing the safety, efficacy, and overall quality of medicines circulating within Nigeria.
An Adverse Drug Reaction (ADR) is defined as any harmful, unintended, or noxious response to a medicinal product that occurs at doses normally used in humans for the prophylaxis, diagnosis, or treatment of disease, or for modification of physiological function. ADRs may occur under approved conditions of use or arise from:
- Drug misuse or Abuse
- Medication Errors
- Drug overdose, Whether accidental or intentional
- Off-label drug use or innappropriate self-medication
- Drug addiction or dependency
As stipulated in NAFDAC’s Pharmacovigilance Guideline (2021), marketing authorization holders, healthcare providers, and patients are encouraged to report all suspected ADRs, including:
- Serious adverse reactions resulting in hospitalization, death, disability, congenital anomaly, or life-threatening conditions.
- Unexpected or rare side effects not previously documented in the product’s information.
- Delayed reactions that may occur after long-term use or discontinuation of the medication.
- Drug-drug or drug-food interactions leading to adverse outcomes.
This commitment reflects our dedication to ensuring the continued safety, quality, and efficacy of our pharmaceutical products throughout their life cycle. We adhere strictly to the provisions of the GVP regulations, which are designed to guide all stakeholders—manufacturers, marketing authorization holders, healthcare professionals, and patients—in fulfilling their roles and responsibilities in drug safety monitoring and reporting.
